BeiGene, Ltd.
BeiGene, Ltd. 6160.HK Peers
See (6160.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 6160.HK | HK$145.00 | -1.89% | 206.6B | -65.91 | -HK$2.20 | N/A |
| 0241.HK | HK$4.65 | -1.90% | 74.9B | 46.50 | HK$0.10 | N/A |
| 3613.HK | HK$8.86 | +2.19% | 7.4B | 14.77 | HK$0.60 | +3.95% |
| 1345.HK | HK$2.10 | -2.33% | 2.5B | 15.21 | HK$0.14 | +4.95% |
| 3390.HK | HK$0.37 | -1.35% | 326.3M | 36.50 | HK$0.01 | N/A |
| 1110.HK | HK$0.57 | +0.00% | 324.3M | 6.88 | HK$0.08 | +5.56% |
| 2211.HK | HK$1.11 | -5.13% | 88.9M | 4.63 | HK$0.24 | N/A |
| 0348.HK | HK$0.07 | +0.00% | 53.9M | -1.40 | -HK$0.05 | N/A |
| 0574.HK | HK$0.03 | +3.45% | 44.2M | -3.00 | -HK$0.01 | N/A |
Stock Comparison
6160.HK vs 0241.HK Comparison
6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6160.HK stands at 206.6B. In comparison, 0241.HK has a market cap of 74.9B. Regarding current trading prices, 6160.HK is priced at HK$145.00, while 0241.HK trades at HK$4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6160.HK currently has a P/E ratio of -65.91, whereas 0241.HK's P/E ratio is 46.50. In terms of profitability, 6160.HK's ROE is -0.12%, compared to 0241.HK's ROE of +0.08%. Regarding short-term risk, 6160.HK is more volatile compared to 0241.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.